Can Fatty Liver Cause Hormonal Imbalance?

Fatty liver disease and hormonal imbalance are more closely connected than many people realise. The liver plays a central role in producing, converting and clearing hormones, so when fat accumulates in liver cells, this process can be disrupted. Known clinically as metabolic dysfunction-associated steatotic liver disease (MASLD, previously NAFLD), fatty liver disease is associated with changes to insulin, sex hormones and thyroid hormones. The relationship is bidirectional: hormonal conditions such as insulin resistance and PCOS can promote fatty liver, which may then worsen the underlying hormonal disruption. Understanding this link is key to managing both conditions effectively.

Can fatty liver really cause hormonal imbalance?

Yes, fatty liver disease can disrupt hormonal balance because the liver is central to producing, converting and clearing hormones. The relationship is bidirectional, with hormonal conditions such as insulin resistance and PCOS also promoting fatty liver.

Yes, fatty liver disease can contribute to hormonal imbalance, because the liver plays a central role in producing, converting and clearing hormones throughout the body. When fat accumulates in liver cells, a condition now termed metabolic dysfunction-associated steatotic liver disease (MASLD, previously called non-alcoholic fatty liver disease or NAFLD), the organ's ability to perform these hormonal functions can become progressively impaired. The term NAFLD remains widely used in UK clinical records, blood test reports and NHS correspondence, so you may encounter both names. The result can be a disruption to the balance of several key hormones, with effects on metabolism, reproduction and overall wellbeing.

The relationship between fatty liver and hormonal imbalance is bidirectional. Hormonal conditions such as insulin resistance, polycystic ovary syndrome (PCOS) and hypothyroidism are recognised risk factors for developing fatty liver in the first place.^[1][7] Once liver disease is established, it may in turn worsen some of the hormonal disruptions that contributed to it, creating a cycle that is difficult to break without addressing both issues simultaneously.

It is important to note that the degree of hormonal disruption varies considerably with disease stage. Early-stage fat accumulation (steatosis) is associated with only mild hormonal effects in most people, whereas more advanced stages involving inflammation (steatohepatitis) or fibrosis tend to be associated with more significant disruption. NICE guideline NG49 on non-alcoholic fatty liver disease emphasises the importance of identifying and managing associated metabolic conditions, which frequently include hormonal disorders.^[1]

Before attributing hormonal or liver symptoms to MASLD, it is worth noting that other causes of liver disease, including excess alcohol intake, viral hepatitis (hepatitis B and C), autoimmune liver conditions and certain medicines, can produce similar findings and should be excluded by your GP. If you are concerned about symptoms that may relate to both liver health and hormonal balance, speaking to your GP is the appropriate first step.

How does the liver regulate hormones in the body?

The liver regulates hormones by synthesising them, converting inactive forms to active ones (such as T4 to T3), and clearing used hormones via bile or urine. It also produces binding proteins like SHBG that control how much free hormone circulates in the blood.

The liver regulates hormones through three principal mechanisms: synthesis, conversion and metabolic clearance. Many hormones are either produced directly in the liver or require liver-based processing before they become biologically active. For example, the liver is one of the main sites at which thyroid hormone thyroxine (T4) is converted into its more active form, triiodothyronine (T3), although the kidneys and other peripheral tissues also contribute to this conversion.^[5][6] The liver also synthesises insulin-like growth factor 1 (IGF-1) in response to signals from growth hormone. When liver function is impaired, these conversions may be affected and circulating hormone levels can shift accordingly.

The liver is also responsible for breaking down and eliminating hormones once they have fulfilled their function. Sex hormones, including oestrogen and testosterone, are metabolised in the liver and excreted via bile or urine. When liver cells are damaged or infiltrated with fat, this clearance process may slow. Clinically significant oestrogen accumulation is more commonly associated with advanced chronic liver disease and cirrhosis than with simple steatosis, though some degree of altered sex-hormone metabolism may occur earlier in the disease course.^[9][10]

Beyond direct hormone handling, the liver produces binding proteins that transport hormones through the bloodstream. Sex hormone-binding globulin (SHBG) is one of the most clinically significant of these. SHBG is produced in the liver, and its levels are associated with insulin resistance and fatty liver disease, with lower SHBG linked to higher free, biologically active sex hormone concentrations in the blood. This may contribute to features associated with PCOS in women and altered androgen balance in men, though the relationship is one of association rather than direct causation. Understanding this central regulatory role helps explain why liver health and hormonal health are closely interlinked.

Which hormones are most affected by fatty liver disease?

Insulin, sex hormones and thyroid hormones are most affected by fatty liver disease. Reduced SHBG, altered oestrogen metabolism and impaired T4-to-T3 conversion are among the most clinically significant associations.

Several hormones are particularly associated with disruption in the context of fatty liver disease, with insulin, sex hormones and thyroid hormones being the most clinically significant. The strength of these associations varies between individuals and tends to be greater with more advanced disease.

Insulin and blood glucose hormones: Insulin resistance is both a cause and a consequence of fatty liver. The liver normally suppresses glucose production in response to insulin, but in fatty liver disease this response can be blunted. The pancreas may compensate by producing more insulin, leading to elevated insulin levels (hyperinsulinaemia), which can further promote fat storage in the liver.

Sex hormones: Reduced SHBG production and altered oestrogen metabolism are recognised associations. In women, these changes may contribute to:

• Irregular or absent menstrual periods

• Features consistent with PCOS, particularly in the context of insulin resistance

• Difficulty conceiving, primarily through the effects of underlying PCOS and insulin resistance rather than fatty liver disease acting alone

In men, elevated oestrogen relative to testosterone can occur, and gynaecomastia (breast tissue development) is a recognised feature, though it is more characteristic of advanced liver disease and cirrhosis than of simple steatosis. Reduced libido and fatigue may also be reported.

Thyroid hormones: Research has identified associations between hypothyroidism and MASLD.^[7] The liver's contribution to T4-to-T3 conversion may be relevant, though the overall relationship is one of association and the evidence base continues to develop.

Cortisol: The liver is involved in cortisol metabolism, and some studies suggest that fatty liver disease may be associated with altered cortisol activity, potentially contributing to central fat distribution and metabolic dysfunction. The evidence in this area is preliminary.

Growth hormone and IGF-1: Reduced hepatic IGF-1 production has been observed in liver disease, which may affect body composition, muscle mass and metabolic rate. The clinical significance in early-stage MASLD is not yet fully established.

Taken together, these associations illustrate why fatty liver disease is increasingly understood as a systemic metabolic condition rather than a problem confined to the liver alone.

What symptoms might suggest both liver and hormone problems?

Fatigue, unexplained weight gain, irregular periods, reduced libido, acanthosis nigricans and upper right abdominal discomfort may indicate overlap between fatty liver and hormonal imbalance. Your GP can arrange liver function tests, HbA1c, thyroid function and hormonal profiles to investigate.

Symptoms that may indicate an overlap between fatty liver disease and hormonal imbalance are often non-specific, which is why the conditions can go unrecognised for some time. Fatigue is among the most commonly reported complaints and can stem from impaired thyroid hormone conversion, insulin resistance or disrupted cortisol metabolism, all of which may occur alongside fatty liver disease. Persistent tiredness that does not improve with rest, particularly when accompanied by weight gain around the abdomen, warrants investigation.

Other symptoms that may suggest both liver and hormonal involvement include:

• Unexplained weight gain or difficulty losing weight despite dietary changes

• Irregular menstrual cycles or worsening PCOS symptoms in women

• Reduced libido or sexual dysfunction in men or women

• Skin changes such as acne, excess hair growth (hirsutism) or skin darkening in body folds (acanthosis nigricans), which can indicate insulin resistance

• Mood changes, low mood or difficulty concentrating

• Discomfort or fullness in the upper right abdomen

Fatty liver disease itself is often silent in its early stages and may only be detected incidentally on an ultrasound or through abnormal liver enzyme results on a blood test. If you experience a combination of the symptoms listed above, your GP can arrange relevant investigations, which may include liver function tests, fasting glucose, HbA1c, thyroid function tests and hormonal profiles. Your GP may also calculate a FIB-4 score (a simple calculation using age, liver enzyme results and platelet count) to assess the likelihood of significant liver fibrosis.^[1][13] If the result is indeterminate or elevated, a second-line blood test called the Enhanced Liver Fibrosis (ELF) test may be arranged, in line with NICE Diagnostics Guidance DG34.^[1] Where advanced fibrosis is suspected, referral to a hepatology specialist will be considered.

Seek urgent medical attention if you develop any of the following, as these may indicate serious liver disease requiring prompt assessment:

• Yellowing of the skin or whites of the eyes (jaundice)

• Dark urine or pale, grey stools

• Vomiting blood or passing black, tarry stools

• Confusion, drowsiness or difficulty thinking clearly

• Severe pain in the upper right abdomen, particularly with fever

• Rapidly increasing abdominal swelling or swelling of the legs and ankles

Early identification matters because both fatty liver disease and associated hormonal imbalances are generally manageable, particularly when addressed through lifestyle changes, weight management and, where appropriate, medical treatment guided by NICE recommendations. Your GP can also check for other causes of abnormal liver results, including alcohol intake, viral hepatitis and medication effects, before attributing findings to MASLD. Do not delay seeking advice if symptoms are affecting your daily life.

Scientific References

1. Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management (NG49).
2. A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
3. Understanding the evolving nomenclature of steatotic liver disease.
4. Non-alcoholic fatty liver disease (NAFLD).
5. Reduced peripheral conversion of thyroxine to triiodothyronine in patients with hepatic cirrhosis.
6. Liver, Portal, and Systemic Thyroid Hormone Concentrations in End-Stage MASH Reveal Distinct Roles for T3/rT3 Ratio and T4.
7. Association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease: an updated meta-analysis.
8. MASLD, diabetes and PMOS across the female life stages.
9. Gynecomastia and cirrhosis of the liver.
10. Steroid hormones and their binding in plasma of male patients with fatty liver, chronic hepatitis and liver cirrhosis.
11. Sexual dimorphism in liver fibrotic metabolic dysfunction: Effects of testosterone and estrogen on CCl4-induced liver fibrosis.
12. Diosgenin Ameliorates Insulin Resistance in High-Fat Diet-Induced Metabolic Dysfunction-Associated Steatotic Liver Disease Rats via the Adiponectin/ADIPOR1/APPL1 Pathway.
13. LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis (MIB317).
14. MRI-based technologies for assessing non-alcoholic fatty liver disease (HTG655) — The diagnostic tests.
15. A Comprehensive Review of Acanthosis Nigricans: Pathogenesis, Clinical Manifestation and Management.
16. Polyendocrine metabolic ovarian syndrome (PMOS).

Frequently Asked Questions